Strategic Signals Weekly

PTC Therapeutics is acquiring ST-920, a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics for an upfront payment of $111 million. The acquisition includes up to $100 million in contingent milestone payments tied to accelerated and traditional FDA approvals. PTC expects to complete a rolling BLA submission for accelerated approval in Q4 2026, based on positive Phase 1/2 data.

Drug: ST-920 · Indication: Fabry disease · Partner: Sangamo Therapeutics, Inc.

ArriVent BioPharma, Inc. entered into a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals Co., Ltd., granting Allist exclusive rights to develop and commercialize ARR-002 in Greater China. ArriVent retains all rights outside this territory and will supply ARR-002 for the initial joint global clinical study. The agreement includes potential payments up to $80.6 million, consisting of an upfront payment, milestones, and tiered royalties.

Drug: ARR-002 · Partner: Shanghai Allist Pharmaceuticals Co., Ltd.

BiomX Inc. entered into a Share Purchase and Option Agreement with Mayers Ventures LLC to acquire 10% of M.E.A. Testing Systems Ltd. (MEA) for $50,000 cash and 1.3 million restricted BiomX shares. This strategic move grants BiomX an exclusive, perpetual worldwide license to MEA's electric motor testing technology, enhancing its capabilities in integrated defense systems. Additionally, BiomX secured an exclusive option to purchase Mayers' remaining 78.9% stake in MEA through June 2028.

Partner: Mayers Ventures LLC

Skye Bioscience, Inc. has entered into a definitive agreement to acquire Redx Pharma Limited through an all-stock scheme of arrangement, subject to shareholder and court approvals. Upon closing, Redx shareholders are expected to own approximately 46.17% of the combined company. The transaction includes a $36.0 million Series A financing for Redx and a concurrent financing for Skye expected to raise $67.9 million, with investors from both financings owning about 48.45% of the combined entity.

Zentalis Pharmaceuticals, Inc. announced a public offering of 23,000,000 shares of common stock at $3.50 per share, expecting to raise approximately $75.1 million in net proceeds. The company plans to use these funds to support clinical trials, preclinical studies, regulatory filings, manufacturing, and general corporate purposes.

Achieve Life Sciences, Inc. established an at-the-market (ATM) offering program with Jefferies LLC, allowing it to sell up to $150.0 million in common stock. The company plans to use the net proceeds for the commercialization of cytisinicline and to fund a Phase 3 clinical trial for cytisinicline for e-cigarette cessation, along with general corporate purposes.

Universal Health Services, Inc. entered into an underwriting agreement to issue and sell $1.1 billion aggregate principal amount of senior secured notes. The offering includes $600 million of 5.500% notes due 2031 and $500 million of 6.000% notes due 2036, underwritten by a syndicate led by J.P. Morgan Securities LLC, BofA Securities, Inc., Truist Securities, Inc., U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC. The proceeds will be used, in part, to repay outstanding borrowings under the Issuer's revolving credit facility.

Aptevo Therapeutics Inc. completed a private placement, generating approximately $4.5 million in aggregate gross proceeds. The financing involved the exercise of existing warrants by certain holders and the sale of new unregistered common stock and associated warrants. The company intends to use the net proceeds for working capital and general corporate purposes.